Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.
The approval is aimed at improving exercise capacity and alleviating symptoms in patients with the condition.
This approval has triggered a $7.5 million milestone payment from Sanofi (NASDAQ:SNY), the company’s partner for the development and commercialization of MYQORZO in Greater China.
In addition to this payment, Cytokinetics is eligible for up to $142.5 million in further development and commercial milestones.
The company will also receive royalties in the low-to-high teens on net sales in Greater China, further bolstering its revenue from the product.
Currently, MYQORZO has been approved only in China.
However, regulatory progress is underway elsewhere: the U.S. New Drug Application (NDA) for MYQORZO is under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date set for December 26, 2025.
In addition, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for MYQORZO on December 12, 2025, with a decision from the European Commission expected in Q1 2026.